Export 2761 results:
Author Title Type [ Year(Asc)]
1996
M. RC, “The progression of myopia in school-age children: data from the Columbia Medical Plan,”, Ophthal Epidemiol, vol. 3, pp. 13-21, 1996.
D. LG, “A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS,”, J Acquir Immune Defic Syndr Hum Retrovirol, vol. 12, pp. 462-9, 1996.
S. Vella, Floridia, M., Dally, L. G., Tomino, C., Fragola, V., Weimer, L. E., Milazzo, F., Mazzotta, F., Moroni, M., Pastore, G., Scalise, G., Sinicco, A., Ortona, L., De Rienzo, B., and Dianzani, F., “A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.”, J Acquir Immune Defic Syndr Hum Retrovirol, vol. 12, no. 5, pp. 462-9, 1996.
N. Oden, Jacquez, G., and Grimson, R., “Realistic power simulations compare point- and area-based disease cluster tests.”, Stat Med, vol. 15, no. 7-9, pp. 783-806, 1996.
O. N, “Realistic power simulations compare point- and area-based disease cluster tests,”, Stat Med, vol. 15, pp. 783-806, 1996.
S. D, “Risk factors for vascular thrombosis (VT) in pediatric renal transplantation,”, 1996.
, “Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120,”, Ann Intern Med, vol. 125, p. 270, 1996.
B. S. Graham, Keefer, M. C., McElrath, M. J., Gorse, G. J., Schwartz, D. H., Weinhold, K., Matthews, T. J., Esterlitz, J. R., Sinangil, F., and Fast, P. E., “Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.”, Ann Intern Med, vol. 125, no. 4, pp. 270-9, 1996.
H. R. H. Stablei DM, “Safety and immunogenicity of env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59,”, AIDS Res Hum Retroviruses, vol. 12, pp. 683-93, 1996.
, “Sensitivity with specificity of a screening questionnaire for dry eye,”, 1996.
S. DM, “Steady improvement in post 1 year half-life of pediatric renal transplants,”, 1996.
E. M. G. Esterli JR, “Trial of calcium for preeclampsia prevention (CPEP): rationale, design and methods,”, Control Clin Trials, vol. 17, pp. 442-69, 1996.
R. J. Levine, Esterlitz, J. R., Raymond, E. G., DerSimonian, R., Hauth, J. C., Ben Curet, L., Sibai, B. M., Catalano, P. M., Morris, C. D., Clemens, J. D., Ewell, M. G., Friedman, S. A., Goldenberg, R. L., Jacobson, S. L., Joffe, G. M., Klebanoff, M. A., Petrulis, A. S., and Rigau-Perez, J. G., “Trial of Calcium for Preeclampsia Prevention (CPEP): rationale, design, and methods.”, Control Clin Trials, vol. 17, no. 5, pp. 442-69, 1996.
C. J, “Vinorelbine Tartrate [in the treatment of breast cancer],”, American Hospital Formulary Service Drug Information, pp. 802-04, 1996.
1995
O. N, “Adjusting Moran’s I for population density,”, Stat Med, vol. 14, pp. 17-26, 1995.
N. Oden, “Adjusting Moran's I for population density.”, Stat Med, vol. 14, no. 1, pp. 17-26, 1995.
S. D, “Analysis of rejection outcomes and implications. A report of the North American Pediatric Renal Transplant Cooperative Study,”, Transplantation, vol. 59, pp. 500-504, 1995.
A. Tejani, Stablein, D., Alexander, S., Fine, R., and Harmon, W., “Analysis of rejection outcomes and implications--a report of the North American Pediatric Renal Transplant Cooperative Study.”, Transplantation, vol. 59, no. 4, pp. 500-4, 1995.
, “Analysis of the NAPRTCS Pediatric Dialysis Registry,”, Clinical Dialysis, vol. 43, pp. 938-43, 1995.
W. MC, “Case-cohort analysis of case-coverage studies of vaccine effectiveness,”, Am J Epidemiol, vol. 142, pp. 1000-6, 1995.
L. H. Moulton, Wolff, M. C., Brenneman, G., and Santosham, M., “Case-cohort analysis of case-coverage studies of vaccine effectiveness.”, Am J Epidemiol, vol. 142, no. 9, pp. 1000-6, 1995.
S. D. Sullivan EK, “Clinical co-relates of graft failure due to chronic rejection in North American children.”, 1995.
B. D. Cheson, Wilson, W. H., and Phillips, P. H., “Clinical trials at the medicine branch of the NCI-part 2.”, Oncology (Williston Park), vol. 9, no. 6, pp. 506, 509-10, 1995.
P. PH, “Clinical trials referral resource. Clinical trials at the Medicine Branch of the NCI-Part II,”, Oncology, vol. 9, pp. 506-9, 1995.
P. PH, “Clinical trials referral resource. Clinical trials at the Medicine Branch of the NCI-Part I,”, Oncology, vol. 9, pp. 292-4, 1995.